12 September 2019 - One reaction to recent amendments to the rules of the federal Patented Medicine Prices Review Board, which sets maximum prices for new medicines in Canada, is that they will not deter pharmaceutical manufacturers from including Canadians in their research trials for drugs for rare disorders.

This is naive thinking. Pharmaceutical manufacturers base decisions on where to invest in trials, not only on favourable clinical environments and reasonable numbers of patients, but also on the likelihood their new medicines will get regulatory approval, will qualify for reimbursement by insurers and will eventually sell at prices that actually generate profits.

Read Financial Post article